ArticleNPJ breast cancer2022

Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.

Hope S Rugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.